CD4 and metabolic dysfunction-associated steatohepatitis: These claims of non- or even anti-inflammatory actions of hepatic DCs are countered by findings that these cells proliferate during NASH concomitant with a decrease in Treg numbers, and promoted the proliferation of CD4+ effector T cells (Th1, Th2 and Th17 cells) (93).